Assessing RET-Altered Tumors: An Increasingly Important Target for Personalized Oncology Care

Learn about the latest clinical data on selective RET inhibitors along with practical guidance to facilitate the detection of RET alterations from leading pathology experts in this dynamic, CME-certified satellite symposium at CAP 2018! Expert faculty will lead discussions and answer your questions on the methodology and testing strategies for RET fusions and mutations.

Sign up today! Registration is complimentary.

This program is not an official event of CAP18 and is not sponsored, endorsed, or accredited by the CAP or any of the cosponsoring organizations of CAP18.

Agenda

6:00 PM - 6:30 PM Dinner and Registration

6:30 PM - 6:35 PM Welcome and Introduction

6:35 PM - 7:00 PM Overview of RET in Oncogenesis and the Role of RET Inhibitors in Cancer Therapy

7:00 PM - 7:50 PM Application in the Clinic

  • Evidence-Based Testing Strategies to Detect RET Fusions and Mutations
  • Appropriate Selection of Patients for Testing for RET Alterations
  • Communication as Part of the Multidisciplinary Team

7:50 PM - 8:00 PM Audience Question and Answer Session and Final Thoughts

Events

Date / Time
Event Details

Faculty

Faculty
Dara L. Aisner, MD, PhD

Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado

Faculty
Eric Q. Konnick, MD, MS

Assistant Professor
Department of Laboratory Medicine
University of Washington
Seattle, Washington

CME

Goal Statement
The goal of this activity is to improve participants’ competence in testing for RET alterations as well as knowledge of the latest data on RET inhibitors to optimize the treatment of patients with cancer

Target Audience 
This program is intended for pathologists and other professionals involved in the detection and analysis of tumor biomarkers in clinical practice.

Learning Objectives 

  • Discuss the concept of “oncogene addiction” and the dependency on a single activated kinase for proliferation and survival in RET fusion cancers and RET-mutant MTC
  • Describe the rationale for testing of RET in lung and thyroid tumors
  • Select evidence-based testing strategies to detect RET fusions and mutations
  • Tailor patient treatment protocols using RET inhibitors as part of a multidisciplinary team collaboration

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.